Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Unexpected Benefits of Bisphosphonates after Hip Fracture

Cathleen Colon-Emeric, MD, MHS  |  Issue: February 2012  |  

 

Dr. Colón-Emeric is associate professor of medicine at Duke University Medical Center and associate director of the Durham VA Geriatrics Research Education and Clinical Center, Durham, N.C.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. www.iofbonehealth.org/facts-and-statistics.html. Updated January 2011.
  2. Fox K, Hawkes W, Hebel J, et al. Mobility after hip fracture predicts health outcomes. J Am Geriatr Soc. 1998;46:169-173.
  3. Zimmerman S, Chandler JM, Hawkes W, et al. Effect of fracture on the health care use of nursing home residents. Arch Int Med. 2002;162:1502-1508.
  4. Colón-Emeric C, Kuchibhatla M, et al. The contribution of hip fracture to risk of subsequent fractures: Data from two longitudinal studies. Osteoporos Int. 2003;14:879-883.
  5. Colón-Emeric C, Casebeer L, Saag K, et al. Barriers to providing osteoporosis care in skilled nursing facilities: Perceptions of medical directors and directors of nursing. J Am Med Dir Assoc. 2004;5:361-366.
  6. Lyles K, Colón-Emeric C, Magaziner J, et al. Zoledronic acid and clinical fracture and mortality after hip fracture. New Engl J Med. 2007;357:1799-1809.
  7. Adachi J, Lyles K, Colón-Emeric C, et al. Zoledronic acid results in better health-related quality of life following hip fracture: The HORIZON–Recurrent Fracture Trial. Osteoporos Int. 2011;22:2539-2549.
  8. Beaupre L, Morrish D, Hanley D, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int. 2011;22:983-991.
  9. Sambrook P, Cameron I, Chen J, et al. Oral bisphosphonates are associated with reduced mortality in frail older people: A prospective five-year study. Osteoporos Int. 2011;22:2551-2556.
  10. Colón-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25:91-97.
  11. Adolphson P, Abbaszadegan H, Boden H, Salemyr M, Henriques T. Clodronate increases mineralization of callus after Colles’ fracture: A randomized, double-blind, placebo-controlled, prospective trial in 32 patients. Acta Orthop Scand. 2000;71:195-200.
  12. Solomon D, Hochberg M, Mogun H, Schneeweiss S. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. Osteoporos Int. 2009;20:895-901.
  13. Colón-Emeric C, Nordsletten L, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011;22:2329-2336.
  14. Pieper CF, Colon-Emetic C, Caminis J, et al. Distribution and correlates of serum 25-hydroxyvitamin d levels in a sample of patients with hip fracture. Am J Geriatr Pharmacother. 2007;5: 335-340.
  15. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ. 2004;328:335-336.
  16. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin Drug Saf. 2007;6:663-672.
  17. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int. 2008;74:641-648.
  18. Eriksen EF, Lyles KW, Colón-Emeric CS, et al. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture. J Bone Miner Res. 2009;24:1308-1313.
  19. Curtis JR, Arora T, Matthews RS, et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dirs Assoc. 2010;11:584-591.
  20. Pham AN, Datta SK, Weber TJ, Walter LC, Colón-Emeric CS. Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy. J Amer Geriatr Soc. 2011;59:1642-1649.

 

Related Articles

    Do Bisphosphonates Reduce Cardiovascular-Related Mortality?

    It is well known that hip fractures are associated with significant morbidity and mortality: Mortality increases 15–25% in the year following a hip fracture.1–5 We know that treating osteo­porosis prevents fractures and improves patient survival. But is there a relationship beyond this? Several studies have found that bisphosphonate therapy is associated with a reduction in…

    Diagnosis, Management of Medication-Induced Osteonecrosis of the Bone

    Prior to the widespread use of bisphosphonates for the manage­ment of osteoporosis, multiple myeloma and metastatic cancer to the skeletal system, osteonecrosis of the jawbones was an infrequent condition seen after radiation for oral cancers (osteoradionecrosis) and in chronic odontogenic infections.1 Since the mid-2000s, osteonecrosis of the jawbones has been noted to occur as a…

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…